Clinical

Treatment strategies for patients with lower-risk MDS are examined.

Biosimilar products may be utilized as treatment options in PNH.

The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance.

A study published in Nature Medicine found that certain tumor mutations are more persistent and may predict immunotherapy responses more reliably than overall tumor mutational burden.

A panel of experts discuss the most important goals of therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma and the largest unmet needs in leukemia/lymphoma.

Brian Koffman, MD, and Callie Coombs, MD, provide the prevalence and incidence rates of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL), and describe how the diagnosis and management of CLL/MCL/SLL impacts a patient’s quality of life.

Callie Coombs, MD, and Brian Koffman, MD, provide an overview of chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and explore the key differences between these disease states.

Cardiovascular risk can be significantly impacted by the presence of diabetes.

Experts highlight key factors when considering costs associated with diabetes treatment pathways.

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.

Paige Nues of the International Rett Syndrome Foundation explores the broader effect on a patient’s family members and caregivers.

Rett syndrome significantly impacts both patient and family’s quality of life.

Bruce Sherman, MD, FCCP, FACOEM, explores how to improve treatment for psoriasis and education surrounding diagnosing psoriasis for all skin phototypes.

Amy McMichael, MD, and Maria Lopes, MD, MS, review factors to evaluate when starting treatment and how to educate patients on the possible adverse events from that treatment.

This new study has found different labs followed similar practices, but the way they scored patients varied significantly.

A new review article shows how technologies like next-generation sequencing might help clinicians tailor care for myelodysplastic syndromes (MDS).

Compared with sorafenib, a combination of sintilimab and a bevacizumab biosimilar improved responses in patients with unresectable hepatocellular carcinoma (HCC).

Clarivate’s “Drugs to Watch” list for 2023 mentions 15 therapeutics, including teplizumab for type 1 diabetes (T1D).

A recent study found that ixazomib was associated with better progression-free survival versus a placebo in multiple myeloma regardless of cytogenetic risk status.

A recent study aggregated RNA sequencing data from more than 3000 samples to create a user-friendly database of transcription profiles in leukemia and related cell lines.

The systemic review and meta-analysis, believe the researchers, is the first of its kind to characterize the prevalence of depression among these patients.

Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.

According to Eli Lilly's statement, the investigational drug worked quickly, so too few patients in the phase 2 study took it for a full year.

Dr De Castro provides an overview of IV versus oral therapies for patients with PNH.

The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.

A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.

Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.

Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.

A panel of experts discuss the value of clinical pathways in MM disease management.